Back to Market返回行情

AXDX Accelerate Diagnostics, Inc.

NASDAQHealthcare
$0.0340+0.00%ClosedMarket Cap: $859,918

As of 2025-05-14 16:00

Why AXDX matters now

Accelerate Diagnostics, Inc. (AXDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.03 with +0.00% on the session and $859.9K in market capitalization.

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

NASDAQ

Beta

0.22

Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.